Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research report sent to investors on Tuesday.

A number of other equities analysts also recently issued reports on ABEO. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $5.88 on Tuesday. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01. The company has a market cap of $255.60 million, a PE ratio of -2.19 and a beta of 1.43. The stock has a 50-day moving average of $5.69 and a 200-day moving average of $5.74. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. abrdn plc lifted its holdings in shares of Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after acquiring an additional 200,647 shares during the last quarter. Rosalind Advisors Inc. lifted its stake in Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 33,831 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics in the third quarter worth about $151,000. Finally, Citigroup Inc. lifted its stake in shares of Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after acquiring an additional 56,332 shares during the last quarter. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.